Background/Aims: To evaluate factors contributing to the decision to initiate treatment with growth hormone (GH) in patients with Turner syndrome (TS). Methods: Data collected included ethnicity, parents’ education and work status, mid-parental height, age at diagnosis, karyotype, pubertal development, clinical severity score, bone age, height SDS and ages when GH was proposed and initiated. Results: GH was proposed to 59 of 72 patients >6 years (82%), and of these 46 (78%) accepted. Reasons for not proposing GH included late diagnosis, good growth and loss to follow-up. GH-treated and untreated girls differed by age at diagnosis (mean ± SD: 6.8 ± 4.7 vs. 4.3 ± 5.1 years; p = 0.04), TS-specific height SDS (0.08 ± 0.81 vs. 066 ± 0.87; p = 0.01) and spontaneous puberty (5/46 vs. 4/26, p = 0.024). Mean age at which it was suggested to begin GH was 9.2 ± 2.9 years. Reasons for parental refusal of GH were not related to reimbursement issues since GH treatment is covered fully by our insurance plan but included concern with other medical issues, mental health problems and fear of injections or unknown side effects. Conclusion: GH treatment was not acceptable to all patients with TS.

1.
Turner H: A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938;28:566–574.
2.
Nielsen J, Wohlert M: Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet 1991;87:81–83.
3.
Sybert VP, McCauley E: Turner’s syndrome. N Engl J Med 2004;351:1227–1238.
4.
Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA: Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet 1997;16:54–63.
5.
Rochiccioli P, David M, Malpuech G, Colle M, Limal JM, Battin J, Mariani R, Sultan C, Nivelon JL, Simonin G, et al: Study of final height in Turner’s syndrome: ethnic and genetic influences. Acta Paediatr 1994;83:305–308.
6.
Lyon AJ, Preece MA, Grant DB: Growth curve for girls with Turner syndrome. Arch Dis Child 1985;60:932–935.
7.
Rongen-Westerlaken C, Corel L, van den Broeck J, Massa G, Karlberg J, Albertsson-Wikland K, Naeraa RW, Wit JM: Reference values for height, height velocity and weight in Turner’s syndrome. Swedish Study Group for GH treatment. Acta Paediatr 1997;86:937–942.
8.
Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gorlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ: Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 1998;132:319–324.
9.
Rochiccioli P, Battin J, Bertrand AM, Bost M, Cabrol S, le Bouc Y, Chaussain JL, Chatelain P, Colle M, Czernichow P, et al: Final height in Turner syndrome patients treated with growth hormone. Horm Res 1995;44:172–176.
10.
Ranke MB, Partsch CJ, Lindberg A, Dorr HG, Bettendorf M, Hauffa BP, Schwarz HP, Mehls O, Sander S, Stahnke N, Steinkamp H, Said E, Sippell W: Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-Up Study 2001. Eur J Endocrinol 2002;147:625–633.
11.
Plotnick L, Attie KM, Blethen SL, Sy JP: Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience. Pediatrics 1998;102:479–481.
12.
Taback SP, Collu R, Deal CL, Guyda HJ, Salisbury S, Dean HJ, Van Vliet G: Does growth-hormone supplementation affect adult height in Turner’s syndrome? Lancet 1996;348:25–27.
13.
Canadian Growth Hormone Advisory Committee: Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–3366.
14.
Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, Lippe B, Pasquino AM, Ranke MB, Rosenfeld R, Silberbach M: Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab 2001;86:3061–3069.
15.
Davenport ML: Evidence for early initiation of growth hormone and transdermal estradiol therapies in girls with Turner syndrome. Growth Horm IGF Res 2006;16:S91–S97.
16.
Bondy CA, Turner Syndrome Study Group: Care of girls and women with Turner syndrome: a Guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 2007;92:1–10.
17.
Frias JL, Davenport ML, Committee on Genetics and Section on Endocrinology: Health supervision for children with Turner syndrome. Pediatrics 2003;111:692–702.
18.
Donaldson MD, Gault EJ, Tan KW, Dunger DB: Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child 2006;91:513–520.
19.
Baxter L, Bryant J, Cave CB, Bryant J, Milne R: Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev 2007;24:CD003887.
20.
Renseignements généraux: Annexe IV-1 Annexe IV: Médicaments d’exception/critères d’utilisation reconnus par le conseil du médicament 2003/10. http://www.ramq.gouv.qc.ca/fr/professionnels/resant/listmed/pdf.
21.
Bender BG, Harmon RJ, Linden MG, Robinson A: Psychosocial adaptation of 39 adolescents with sex chromosome abnormalities. Pediatrics 1995;96:302–308.
22.
Bannink EM, Raat H, Mulder PG, de Muinck Keizer-Schrama SM: Quality of life after growth hormone therapy and induced puberty in women with Turner syndrome. J Pediatr 2006;148:95–101.
23.
Carel JC, Ecosse E, Bastie-Sigeac I, Cabrol S, Tauber M, Leger J, Nicolino M, Brauner R, Chaussain JL, Coste J: Quality of life determinants in young women with Turner’s syndrome after growth hormone treatment: results of the StaTur population-based cohort study. J Clin Endocrinol Metab 2005;90:1992–1997.
24.
Tanner JM, Goldstein H, Whitehouse RH: Standards for children’s height at ages 2–9 years allowing for height of parents. Arch Dis Child 1970;45:755–762.
25.
Gilli G: The assessment of skeletal maturation. Horm Res 1996;45(suppl 2):49–52.
26.
Sybert VP: Adult height in Turner syndrome with and without androgen therapy. J Pediatr 1984;104:365–369.
27.
Ferguson-Smith MA: Genotype-phenotype correlations in the Turner syndrome; in Hibi I, Takano K (eds): Basic and Clinical Approach to Turner Syndrome. Amsterdam, Elsevier, 1993, pp 17–26.
28.
Sybert VP: Phenotypic effects of mosaicism for a 47,XXX cell line in Turner syndrome. J Med Genet 2002;39:217–220.
29.
Cohen A, Kauli R, Pertzelan A, Lavagetto A, Roitmano Y, Romano C, Laron Z: Final height of girls with Turner’s syndrome: correlation with karyotype and parental height. Acta Paediatr 1995;84:550–554.
30.
Byrd MW, Clayton LA: Racial and ethnic disparities in health care: a background and history; in Institute of Medicine (US), Smedley BD, Stith AY, Nelson AR (eds): Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, The National Academies Press, 2003, pp 455–527.
31.
Poitras L, Charest J, Froissard S, Beauchamp C: The levels of care at Sainte-Justine Hospital: a comparative provincial analysis. Report from the Department of Professional Services. Montreal, Sainte-Justine Hospital, 2001, pp 25–30.
32.
Rosenfield RL, Devine N, Hunold JJ, Mauras N, Moshang T Jr, Root AW: Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome. J Clin Endocrinol Metab 2005;90:6424–6430.
33.
Ito Y, Fujieda K, Tanaka T, Takano K, Chihara K, Seino Y, Irie M: KIGS (Pfizer International Growth Study) Japan Scientific Committee: Low-dose growth hormone treatment (0.175 mg/kg/week) for short stature in patients with Turner syndrome: data from KIGS. Japan Endocr J 2006;53:699–703.
34.
van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL: Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88:1119–1125.
35.
Ranke MB, Lindberg A, Ferrandez Longas A, Darendeliler F, Albertsson-Wikland K, Dunger D, Cutfield WS, Tauber M, Wilton P, Wollmann HA, Reiter EO: KIGS International Board: major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res 2007;61:105–110.
36.
Soriano-Guillen L, Coste J, Ecosse E, Leger J, Tauber M, Cabrol S, Nicolino M, Brauner R, Chaussain JL, Carel JC: Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone. J Clin Endocrinol Metab 2005;90:5197–5204.
37.
Carel JC: Growth hormone in Turner syndrome: twenty years after, what can we tell our patients? J Clin Endocrinol Metab 2005;90:3793–3794.
38.
Massa G, Verlinde F, De Schepper J, Thomas M, Bourguignon JP, Craen M, de Zegher F, Francois I, Du Caju M, Maes M, Heinrichs C, Belgian Study Group for Paediatric Endocrinology: Trends in age at diagnosis of Turner syndrome. Arch Dis Child 2005;90:267–268.
39.
Massa GG, Vanderschueren-Lodeweyckx M: Age and height at diagnosis in Turner syndrome: influence of parental height. Pediatrics 1991;88:1148–1152.
40.
Stochholm K, Juul S, Juel K, Naeraa RW, Gravholt CH: Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. J Clin Endocrinol Metab 2006;91:3897–3902.
41.
Carel JC, Mathivon L, Gendrel C, Ducret JP, Chaussain JL: Near normalisation of final height with adapted doses of growth hormone in Turner’s syndrome. J Clin Endocrinol Metab 1998;83:1462–1466.
42.
Massa G, Vanderschueren-Lodeweyckx M, Malvaux P: Linear growth in patients with Turner syndrome: influence of spontaneous puberty and parental height. Eur J Pediatr 1990;149:246–250.
43.
Lagrou K, Xhrouet-Heinrichs D, Heinrichs C, Craen M, Chanoine JP, Malvaux P, Bourguignon JP: Age-related perception of stature, acceptance of therapy, and psychosocial functioning in human growth hormone-treated girls with Turner’s syndrome. J Clin Endocrinol Metab 1998;83:1494–1501.
44.
Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, Gunther DF, Liu C, Geffner ME, Thrailkill K, Huseman C, Zagar AJ, Quigley CA: Growth hormone treatment of early growth failure in toddlers with Turner syndrome (TS): a randomized, controlled, multi-center trial. J Clin Endocrinol Metab 2007;92:3406–3416.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.